Yodantipyrine

Iodantipyrine refers to antiviral drugs with a narrow spectrum of action, which have anti-inflammatory properties.

Indications Yodantipyrine

Indications for use of Jodantipyrine are:

• Tick-borne encephalitis in adults;
• prevention of the occurrence of tick-borne encephalitis in case of detection of a sucking mite (before going to medical institutions) or the presence of such a threat in the natural foci of tick-borne encephalitis;
• when a sucking mite is found in people who have previously been vaccinated against tick-borne encephalitis;
• hemorrhagic nephroso-nephritis (hemorrhagic fever with renal syndrome).

[1], [2], [3], [4], [5],

Release form

Form release of the drug Yodantipirin - tablets of 0.1 g (100 mg).

[6], [7]

Pharmacodynamics

Pharmacodynamics Iodantipirin is based on the active substance of the drug, the combination of pyrazolone - 1-phenyl-2,3-dimethyl-4-iodopyrazolone, which is active against neuronal viruses of tick-borne encephalitis, as well as viruses carried by ixodic and gamasid mites that cause hemorrhagic fever with nephrosyndrome.

When it enters the bloodstream, Yodantipirin activates alpha and beta interferon, which improves coordination of biochemical processes in the body's lymphatic system, and immunity at the cellular level is significantly increased. Stabilization of cell membranes helps prevent the introduction of viral cells into them. Thus, the effect of this drug on antigens can be considered immunomodulating.

[8], [9], [10], [11], [12]

Pharmacokinetics

After taking the drug Yodantipirin it is absorbed for a short time from the digestive tract into the blood, 25% of the active substance binds to blood plasma proteins. After 10-12 hours, the maximum concentration of the drug in the tissues is reached. The level of bioavailability is not less than 80%.

Transformation of about 95% of 1-phenyl-2,3-dimethyl-4-iodopyrazolone occurs in the liver, passive metabolites amount to 90%. Metabolites and unsplit part of the drug are excreted through the kidneys with urine, the half-life period is approximately 6 hours.

[13], [14], [15], [16], [17], [18], [19],

Dosing and administration

For the treatment and prevention of tick-borne encephalitis (in the case of a sucking mite), the following scheme of taking Yodantipirin is prescribed:

• the first two days - 3 tablets (0.3 g), three times a day;
• on the third and fourth days - 2 tablets (0.2 g), in three divided doses;
• for the next 5 days - one tablet, 3 times a day.

For the purpose of prevention during the stay in the natural foci of tick-borne encephalitis, the recommended dosage of the drug is 2 tablets once a day.

For the treatment of hemorrhagic fever with renal syndrome, Yodantipirin is administered in the first five days after the onset of symptoms of the disease. The recommended standard dose is 2 tablets (0.2 g) - three times a day (for 4 days), then another 5 days should be taken one tablet 3 times during the day.

[24], [25], [26]

Use Yodantipyrine during pregnancy

This drug is certified only in the Russian Federation, there have not been any substantive clinical trials for its teratogenicity. Therefore, the use of Yodantipirin during pregnancy, as well as during breastfeeding is contraindicated.

Contraindications

Yodantipirin is contraindicated for individual hypersensitivity to iodine-containing drugs, in the presence of pathologies of the thyroid gland (hyperfunction), expressed hepatic and renal insufficiency, in patients under the age of 18 years.

[20], [21]

Side effects Yodantipyrine

The use of this drug can cause such side effects as skin rashes, itching of the skin, dyspeptic phenomena, angioedema. Also, other reactions of an allergic nature are not excluded.

[22], [23]

Overdose

An overdose of this drug may be manifested by an increase in its side effects, as well as symptoms of iodism. Among such symptoms are: inflammation of the mucous membranes of the upper respiratory tract as laryngitis or tracheitis, runny nose, increased salivation, metal taste in the mouth, lacrimation, conjunctivitis, fever, general weakness, intestinal disorders, papular rashes on the skin.

[27], [28], [29], [30], [31], [32]

Interactions with other drugs

With the simultaneous administration of Yodantipirin with anti-heartburn and H2 receptor antagonists, the level of its absorption in the gastrointestinal tract decreases.

Interacting with hypoglycemic drugs for the treatment of diabetes, hypnotic groups of barbiturates, tricyclic antidepressants and anticoagulant drugs, Yodantipirin is able to enhance their effect.

It is also not recommended to use Yodantipirin together with anti-malignant immunoglobulin.

[33], [34], [35]

Storage conditions

Storage conditions Yodantipyrine: in a dark place at a temperature not higher than + 24-25 ° C.

Shelf life

Shelf life of the drug is 24 months.

[36], [37], [38], [39]